Prolaris for Prostate Cancer Patients

Prolaris is a genomic test developed to aid healthcare professionals in predicting the aggressiveness of prostate cancer in conjunction with clinical parameters such as Gleason score and PSA.

Prolaris was the first test to offer a direct measure of the molecular biology of an individual patient’s prostate cancer. By measuring the expression levels of genes involved in cancer cell proliferation, Prolaris is able to accurately predict disease aggressiveness.

Prolaris has been shown to be the single most clinically significant prognostic parameter of outcomes at the time of diagnosis. The test provides unique additional information combined with standard clinical factors to make the most accurate prediction of a patient’s prostate cancer aggressiveness. Prolaris has been extensively validated across multiple patient cohorts in conservative management and definitive treatment settings.

Local and Central Testing

Prolaris is available as a service provided by Myriad Genetics and, pre-treatment, also as a CE-IVD kit that can be run in local molecular pathology laboratories.

This enables the pathologist to provide results within a few days. Treatment decisions can be made without unnecessary delay to maximize patient benefit.

Prolaris consistently delivers the same quality of results, regardless of the certified laboratory conducting the assay.

Prolaris Predicts the Risk of Disease Progression within Ten Years

Prolaris, performed on FFPE biopsy samples, determines patients’ individual 10-year risk of prostate cancer specific mortality when conservatively managed, and 10-year metastasis risk after definitive therapy (surgery or radiation).

Prolaris, on FFPE resected prostate tumors (only available as a service provided by Myriad Genetics), determines biochemical recurrence risk within 10 years after prostatectomy.

It can enable healthcare professionals to better define a treatment/monitoring strategy for their patients:

  • At diagnosis, Prolaris can help to identify patients with less aggressive cancer who may be candidates for active surveillance. Prolaris can also identify patients who appear to be clinically low risk but have a more aggressive disease that requires more extensive treatment.
  • Prolaris post-prostatectomy testing helps to better estimate a patient’s risk of disease recurrence and therefore adjust the level of monitoring or add additional therapy.

Learn more about Prolaris